Early Screening for Type 1 Diabetes: A New Path for Pediatric Care

For decades, screening for type 1 diabetes in the United States has been largely restricted to children with a known family history of the disease or those with a documented genetic risk. However, a significant 10-year study published on May 21, 2026, in the Journal of the American Medical Association suggests that this approach may be missing a vast majority of those at risk. With approximately 90 percent of people who develop type 1 diabetes lacking a family history of the condition, experts are increasingly calling for a shift toward general population screening.

The Case for Universal Screening

The research, which monitored more than 220,000 children, highlights a critical gap in current diagnostic protocols. By expanding screening beyond those with a family history, researchers successfully identified 590 children in the early, asymptomatic stages of the disease. Most importantly, of the 260 children who progressed to clinical type 1 diabetes during the study, 212—or 81 percent—had been identified through the screening process. Had the program been limited to those with a family history, the vast majority of these children would have gone undetected until symptoms appeared.

Type 1 diabetes is an autoimmune condition where the body’s immune system destroys insulin-producing beta cells in the pancreas. Because the early stages are asymptomatic, many children are not diagnosed until they experience a medical emergency known as diabetic ketoacidosis (DKA). DKA occurs when insulin levels drop so low that the body begins breaking down fat for energy, causing dangerous levels of acid to accumulate in the blood. In the United States, 30 to 40 percent of children are diagnosed only after reaching this life-threatening state.

Understanding the Stages of Type 1 Diabetes

Early detection allows for medical intervention before the onset of clinical symptoms or the development of DKA. The progression of the disease is generally categorized as follows:

• Stage 1: The body has begun destroying beta cells, but blood glucose levels remain normal. This stage is confirmed by the presence of two or more autoantibodies in the blood.
• Stage 2: Two or more autoantibodies are present, and blood glucose levels have begun to show abnormalities.
• Stage 3: The clinical onset of the disease, characterized by clear symptoms and significant beta-cell loss.

Children in the early stages face an 85 percent or higher risk of progressing to stage 3 within 15 years. Early identification changes the trajectory for these families, shifting the experience from an emergency diagnosis to a managed health journey.

New Opportunities for Intervention

Beyond the benefits of early monitoring and education, medical advancements are providing new ways to delay the disease. Teplizumab, a medication approved for children and adults in stage 2, works to prevent the destruction of beta cells. Research published in the New England Journal of Medicine in 2019 demonstrated that a 14-day infusion of this medication could delay the progression to clinical type 1 diabetes by approximately four years, compared to roughly two years in a placebo group.

Jennifer Sherr, a pediatric endocrinologist at the Yale School of Medicine, notes that such delays can be life-changing. “It’s amazing to think about having that time” before a child must begin the daily, lifelong burden of insulin therapy, Sherr says. By delaying the onset, children may reach a more mature age before needing to manage the complexities of insulin injections and constant blood sugar monitoring.

Looking Ahead

The success of the German study provides a compelling argument for broader screening initiatives. While current U.S. Efforts remain focused on specific regional implementations, such as pilot studies in the Dakotas and Colorado, the data suggests that universal screening could be a vital tool in public health. By catching the disease early, we can protect children from the dangers of diabetic ketoacidosis and provide families with the time and resources needed to prepare for the road ahead.

Key Takeaways

• Broad Impact: Approximately 90 percent of people who develop type 1 diabetes have no family history of the disease.
• Improved Detection: A 10-year study found that universal screening identified 81 percent of children who eventually developed clinical type 1 diabetes.
• Preventing Emergencies: Early detection is key to avoiding diabetic ketoacidosis, a life-threatening complication present at diagnosis for up to 40 percent of U.S. Children.
• Therapeutic Advances: Medications like teplizumab can delay the onset of clinical diabetes, offering patients several years without the need for daily insulin.